News18 min read
Chinese Peptides: The Gray Market Biohacking Trend Explained
What are "Chinese peptides"? A science-backed analysis of the gray market biohacking trend, safety risks, contamination data, legal status, and how to protect yourself.
News
Industry updates and market analysis.
News16 min read
Peptide Nanotechnology: Drug Delivery Advances
Getting a drug to the right place in the body is often harder than making the drug itself. Cancer therapies that could destroy tumors also poison healthy tissue. Brain drugs that work in the lab cannot cross the blood-brain barrier.
News11 min read
Global Peptide Research Hubs: US, EU, Asia-Pacific
Peptide science has become a global enterprise. With over 100 FDA-approved peptide drugs on the market and a therapeutics sector projected to exceed $100 billion by 2033, institutions worldwide are racing to discover, synthesize, and deliver the next generation of peptide-based medicines.
News12 min read
Peptide Manufacturing Scale-Up Challenges
Making a peptide in a lab is chemistry. Making a million doses of it is engineering, economics, and logistics — and the peptide industry is struggling with all three.
News13 min read
How COVID-19 Accelerated Peptide Research
The pandemic didn't just disrupt daily life — it reshaped the trajectory of peptide science. Between early 2020 and 2023, COVID-19 drove a wave of research funding, clinical experimentation, and public interest that pushed peptides from niche academic study into mainstream biomedical conversation.
News13 min read
Venture Capital in Peptide Startups: 2026 Funding
Investor interest in peptide drug development surged in 2025, with major rounds for obesity, macrocyclic, and oral-delivery platforms. This piece breaks down the year's defining deals and where the money is headed next.
News14 min read
Peptide Delivery Innovations: Patches, Implants, Orals
Most peptide drugs arrive in the body the same way they did 30 years ago: through a needle. Subcutaneous injections work, but they impose a burden that limits who will use peptide therapies and how consistently they'll take them. Needles hurt. They require cold-chain storage.
News12 min read
The GLP-1 Effect on Bariatric Surgery Rates
In 2022, bariatric surgery programs across the United States hit record volumes — 280,000 procedures, the culmination of a decade of steady growth. Two years later, national data showed a 38% decline. The University of Pennsylvania Health System went from 850 annual surgeries to around 400.
News13 min read
The Role of Peptides in Personalized Medicine
One-size-fits-all medicine is a poor fit for peptide therapeutics. A patient on semaglutide might lose 20% of their body weight while another loses 5% — same drug, same dose, vastly different outcomes.
News14 min read
Generic Peptide Drugs: Biosimilar Pipeline
As patents on blockbuster peptide drugs like semaglutide and tirzepatide start to expire, this guide explains why making a generic peptide differs from a generic small-molecule drug, and maps the regulatory pathways and manufacturers involved.
News12 min read
Peptide Cosmetics Market: Growth & Innovation
Peptides are the fastest-growing active ingredient category in skincare. The global peptide cosmetics market hit $2.3 billion in 2024 and is projected to exceed $6.5 billion by 2033 — a 12.3% compound annual growth rate.
News13 min read
Peptide Conferences & Events Calendar 2026
The peptide field's biggest gatherings in 2026 span industry conferences aimed at translating peptide science into drugs, academic meetings on peptide biology, and specialized events for niche applications, with details on what each one covers.
News12 min read
Peptide Therapy Clinics: Industry Growth Analysis
GLP-1 drugs and the biohacking movement turned peptide clinics into one of wellness medicine's fastest-growing segments. This analysis covers market size, business models, and patient demand driving that growth.
News14 min read
The Peptide Biohacking Movement: History & Trends
Peptide use began as a fringe biohacking practice on niche forums before becoming a mainstream wellness category. This piece traces the movement's origins, key figures, and the risks that have followed its growth.
News16 min read
Peptide Synthesis Industry: Market & Technology Trends
GLP-1 drugs turned peptide manufacturing from a niche specialty business into an industry racing to scale. Here is how market size, demand, and synthesis technology are shifting to keep up.
News12 min read
AI & Machine Learning in Peptide Discovery
Traditional peptide drug development is slow and expensive, but AI-enabled workflows are cutting discovery timelines from years to months. Here is how structure prediction and generative design are reshaping the pipeline.
News13 min read
Next-Generation GLP-1 Drugs: What's Coming After
Semaglutide and tirzepatide reshaped obesity treatment, but they remain first-generation tools. Here is what the next wave of GLP-1 drugs aims to do differently, from triple agonists to muscle-sparing approaches, and where the clinical data stands.
News13 min read
The Economics of GLP-1: Impact on Food & Pharma
With over a tenth of U.S. adults now taking a GLP-1 drug, the ripple effects reach grocery stores, restaurants, and pharma revenue models. This piece tracks the spending data behind the shift.
News10 min read
Major Peptide Clinical Trial Results Expected 2026
Four obesity and metabolic drugs are reporting Phase 3 data in 2026: retatrutide, survodutide, orforglipron, and CagriSema. Here is what each trial program is testing and why the results matter.
News16 min read
The Counterfeit Peptide Problem: Industry Response
Unregulated demand for peptides has fueled a gray market of counterfeit and substandard products. This piece looks at how fabrication and mislabeling happen, what testing reveals, and how the industry is responding.
News13 min read
Social Media & Peptides: TikTok, Reddit, Influence
Peptide awareness caught fire on social media, starting with GLP-1 drugs and spreading to research peptides. This piece traces how TikTok, Reddit, and podcasts shaped what the public thinks it knows about peptides.
News15 min read
The Compounded Semaglutide Controversy Explained
Compounded semaglutide grew from a pharmacy shortage exception into a fight involving the FDA, federal courts, telehealth platforms, and Novo Nordisk. Here is how the controversy unfolded and where it stands.
News12 min read
GLP-1 Drug Pricing: Global Comparison & Access
The same semaglutide injection pen can cost nine times more in the United States than in the United Kingdom or India. This article maps what patients pay for GLP-1 drugs worldwide and what drives the differences.
News12 min read
Insurance Coverage for GLP-1 Drugs: 2026 Update
GLP-1 drugs work, but at list prices above $1,000 a month, whether insurance pays is what determines access. Here is where Medicare, employer plans, and prior authorization rules stand as of early 2026.
News12 min read
Celebrity Endorsements & the GLP-1 Phenomenon
Semaglutide was developed and approved for type 2 diabetes, but celebrity disclosures beginning in 2022 turned it into a household name for weight loss. This piece traces the disclosure timeline and how social media accelerated GLP-1 prescriptions nationwide.
News18 min read
GLP-1 Drugs & the Obesity Treatment Revolution
Semaglutide and tirzepatide produced weight loss results unlike any prior medication, prompting the WHO to classify obesity as a chronic disease and issue its first guideline on GLP-1 use. This article covers the science and scale of the shift.
News14 min read
Peptide Compounding Industry After FDA Crackdown
Starting in January 2025, the FDA revised its interim policy on bulk drug substances, closing loopholes that had allowed widespread peptide compounding. Here is what changed, why it hit compounding pharmacies and telehealth platforms hardest, and what it means for patients.
News13 min read
The Rise of Oral Peptide Drugs: Industry Analysis
Peptides are normally destroyed by digestion, which kept them confined to injections for most of pharmaceutical history. This analysis covers the SNAC absorption-enhancer technology now making oral peptide drugs possible.
News12 min read
New Peptide Drugs in FDA Pipeline (2026-2028)
The FDA approved four peptide and oligonucleotide drugs in 2024 and 46 novel drugs overall in 2025, with the next three years expected to bring a wave of peptide approvals spanning obesity, autoimmune disease, and cancer care.
News11 min read
Top Peptide Companies to Watch in 2026
The peptide therapeutics market spans big pharma, manufacturing specialists, and early-stage startups with novel platforms. This roundup looks at the companies shaping the space in 2026 and why each one matters.
News11 min read
Peptide Therapeutics Market Size & Growth Forecast
Semaglutide and tirzepatide turned peptide drugs into pharma's fastest-growing category. This breakdown covers current market valuation, the forces behind the growth, and where funding is flowing.
News13 min read
Novo Nordisk vs. Eli Lilly: The GLP-1 Market War
Novo Nordisk and Eli Lilly have both built their modern identities around GLP-1 receptor agonists, but after a year of diverging trajectories, the competition between them looks less like a rivalry and more like a rout.
News11 min read
GLP-1 Market Update: Q1 2026 Revenue & Trends
Eli Lilly is surging, Novo Nordisk is stumbling, patent cliffs are approaching, and oral GLP-1 formulations just reached pharmacy shelves. Here is where the GLP-1 market's numbers stand in early 2026 and what they signal for the rest of the year.
News12 min read
Peptide Industry News: Weekly Roundup Template
The peptide space moves fast, with new trial results, regulatory shifts, and research breakthroughs landing every week. Here is how PeptideJournal approaches industry coverage, followed by a sample roundup that shows the format in action.